Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

Y0001237

Nimesulide for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Nimesulide, N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide

Sign Into View Organizational & Contract Pricing

Select a Size

10 MG
$156.00

$156.00

Check Cart for Availability
Request a Bulk Order
All Photos(1)

Select a Size

Change View
10 MG
$156.00

About This Item

Empirical Formula (Hill Notation):
C13H12N2O5S
CAS Number:
51803-78-2
Molecular Weight:
308.31
MDL number:
MFCD00079470
UNSPSC Code:
41116107
PubChem Substance ID:
329831316
NACRES:
NA.24

$156.00

Check Cart for Availability
Request a Bulk Order

grade

pharmaceutical primary standard

API family

nimesulide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CS(NC1=C(OC2=CC=CC=C2)C=C([N+]([O-])=O)C=C1)(=O)=O

InChI

1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3

InChI key

HYWYRSMBCFDLJT-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Nimesulide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Highly selective cyclooxygenase-2 inhibitor.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Francesco Guido Mangano et al.
Clinical oral implants research, 25(8), 933-940 (2013-04-30)
The aim of this study was to evaluate the long-term outcome of short (8-mm) locking-taper implants supporting single crowns in the posterior regions and to analyze the influence of different factors on implant survival and implant-crown success rates. Between June
Lorena Pochini et al.
Biochemical pharmacology, 89(3), 422-430 (2014-04-08)
The effect of pharmaceutical compounds on the rat kidney B0AT1 transporter in proteoliposomes has been screened. To this aim, inhibition of the transport activity by the different compounds was measured on Na(+)-[(3)H]glutamine co-transport in the presence of membrane potential positive
Eduardo Candelario-Jalil
Pharmacological research, 57(4), 266-273 (2008-04-29)
Nimesulide is a preferential inhibitor of cyclooxygenase-2 (COX-2) and it is one of the most prescribed non-steroidal anti-inflammatory drugs (NSAID) worldwide. Nimesulide was recently shown to have neuroprotective properties in animal models of acute neurologic injury. In particular, nimesulide is
Muhammad Hanif et al.
Pakistan journal of pharmaceutical sciences, 27(4), 785-792 (2014-07-13)
Simple and cost effective study consisting of three steps, comparison of micromeritic properties of different blends i.e. placebo without API and Nimesulide containing, Use of central composite design (CCRD) for intermediate release Nimesulide tablets and stability results of three selected
C Mattia et al.
Minerva medica, 101(4), 285-293 (2010-10-30)
The first marketing authorization for nimesulide was approved in Italy in 1985. After one quarter of a century we evaluate its peculiar characteristics compared with other NSAIDs. Nimesulide is the only NSAID related to the arylsulfonamide class and is a
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service